Navigation Links
Regenetek Research Inc. Launches New Intelligent Software for Therapeutic Stem Cell Trials
Date:12/11/2012

WINNIPEG, Manitoba, Dec. 11, 2012 /PRNewswire/ -- Doug Broeska, Ph.D., CEO of Regenetek Research Inc., an international medical research company with offices in Canada and India has announced that they are launching new web-based, self-managing, clinical trial software that amongst other things will be able to extend patient Registry information into individual patient case studies and aggregate the data with comparisons to cohorts. The company has so far specifically focused their new technology on a number of autologous therapeutic stem cell trials for a range of neurologic diseases that are taking place in multiple centers worldwide. Such software would have important application where limited financial resources are combined with the need to validate efficacy and prove reproducibility of therapy protocols.

"The ability to rigorously evaluate individual patients, monitor adverse events, and aggregate data from different patients in different centers while maintaining ethical standards will achieve better control of bias, generate greater statistical power, and produce more meaningful conclusions for clinical outcomes," says Dr. Broeska, CEO of Regenetek Research. Indeed, for cases where every patient's cells are unique, randomized controlled trials are simply not possible as an appropriate design for clinical investigation.

"This is just getting back to the basics of medical research. A lot of medical investigation used to be done this way," says Broeska. "Many medical breakthroughs were made only through observations with an N of one, but now we have the advantage of being able to handle big data through new technologies. We can chart the outcomes of many individual patient case studies over time, aggregate, and even compare the data in a meaningful way to produce valid evidence. We are not limited to therapeutic stem cell research but that is an obvious place to start. Moving all medical investigation forward, faster is our goal."

Inquiries may be directed to Dr. Doug Broeska at "info@regenetek.com" or call 204-975-9665.

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Regenetek Research Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Scientific Research & Development in the US Industry Market Research Report from IBISWorld has Been Updated
2. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
3. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
4. UT Arlington research team wins $1.35 million NSF robotics grant to develop smart skin applications
5. Premier Biomedical Successfully Advances Cancer Research
6. US Natural Polymers Market Forecasts to 2016 in New Research Report at ReportsnReports.com
7. Leuven research opens new pathway for the treatment of Alzheimers disease
8. Industrial carbon management research gets $3.75 million boost
9. Diabetes Research Institute Foundation’s (DRIF) CEO Joins Healthcare Holdings Group, Inc. Board of Directors
10. ArteryHealth.org Launches as a Collective Database of Artery Health Research
11. Research discovery could revolutionize semiconductor manufacture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):